Impact of Hyperthermia on Quality of Life (QoL): Pain Relief, Fatigue Reduction, and Adjuvant Immunological Benefits
1. Major Palliative Benefit: Pain Control (level A1 evidence from Phase III clinical trials)
Metastatic bone pain degrades QoL. Locoregional RF Hyperthermia, combined with Radiotherapy (RT), provides superior palliative control, according to the *Phase III* study published by Chi MS et al . (2017)[1]:
| QoL Indicator/Pain Improvement | RT monotherapy | RT + Hyperthermia (HT) | Impact QoL |
|---|---|---|---|
| Complete Response Rate (CR) at 3 Months (zero pain score) | *7,1 %* | *37,9 %* | *533% increase* in the chances of total pain relief. |
| Duration of Pain Relief | Median: *55 days/7.9 weeks* | Median: *Not included at 24 weeks* | The duration of relief *triples*, reducing dependence on painkillers. |
In 2024, Sahinbas and colleagues published a phase III study for bone metastases pain mainly from breast and prostate cancer using WBHT wIRA hyperthermia in addition to RT [2].
Based on this study, the radiotherapy (RT) alone group presented the most intense pain. The study was completed after enrolling a total of 61 patients, 5 years after first enrollment (April 2016 – February 2021). Finally, the CR rate in the RT + WBH group showed the most significant difference with RT alone, 47.4% vs. 5.3%, respectively, within 2 months post-treatment (P value < 0.05). The time to complete pain relief was 10 days for RT + WBH, while the endpoint was not reached in the RT alone group. Pain progression or disease stability was observed in half of the patients in the RT group within 4 weeks after treatment. However, this score was close to zero in RT + WBHT patients within two months post-treatment.
Conclusions: WBH plus RT demonstrated significant increases in pain relief and shorter response time compared with RT alone in patients with metastatic bone lesions.
| QoL Indicator/Pain Improvement | RT monotherapy | RT + Hyperthermia (WBHT wIRA) | Impact QoL |
|---|---|---|---|
| Complete Response Rate (CR) at 2 months (zero pain score) | *5,3 %* | *47,4 %* | * 894% increase * in the chances of total pain elimination. |
| Time to complete pain relief | was not touched | 10 days | ” significcate and rapid” benefit |
| Duration of Pain Relief | Median: *28 days/4 weeks* in half of patients | Median: *Not included at 24 weeks* | The duration of relief * increases sixfold *, reducing dependence on painkillers. |
2. Improving Functional Status and Reducing Fatigue
The benefit of HT on QoL is directly measurable through standardized questionnaires (EORTC QLQ-C30), showing an improvement in general condition (Physical Function, Fatigue and Anxiety):
- Significantly Improved QoL (modulated RF hyperthermia mHT): A randomized clinical trial of Modulated RF Hyperthermia (mEHT) in Cervical Cancer (CCC) reported a *significant improvement in long-term QoL scores*, with patients reporting better scores on the *Physical and Emotional Functioning* scales.[3]
- Fatigue Control and Immunomodulation: Whole Body Hyperthermia (WBHT) and HT in general positively influence *chronic fatigue syndrome (CRF)* by modulating pro-inflammatory cytokines (IL-6, TNF-alpha). HT also helps maintain and improve scores on *Physical and Emotional Functioning* scales in the long term.[4]
- Rapid Emotional Recovery (HIPEC): After major surgical procedures that include HT (HIPEC), emotional QoL tends to *improve rapidly, starting as early as *3 months* post-operatively, often exceeding baseline levels.[5]
3. Consolidating Long-Term QoL Benefits
Real-world data and clinical trials in advanced cancers reinforce the role of Hyperthermia in stabilizing and improving long-term QoL:
- Curative Impact at 12 Months: An extensive analysis of patients treated with curative intent (RCT + HT) showed a significant improvement, maintained over a 12-month period, in scores on the QoL subscales assessing Emotional Function, Social Function and Insomnia (SL), compared to the EORTC oncology reference population.[10]
- Palliative Benefits: In a palliative context, the addition of HT to standard treatment led to a clinically relevant improvement in Pain (PA) and a reduction in Financial Difficulties (FI) 3 months after treatment, contributing to a better overall patient condition.[10]
- Improved QoL in Advanced Disease (Colorectal Cancer): In a study evaluating Chemotherapy-Assisted High Frequency Hyperthermia in patients with intermediate and advanced stage Colorectal Cancer, the group receiving the combination showed significantly higher (improved) QoL scores after 4 cycles of treatment, demonstrating that HT effectively improves QoL, in addition to therapeutic effects, while maintaining better safety.[11]
4. Adjuvant Biological Benefits and Superior Therapeutic Index
HT maximizes treatment lethality without significantly increasing the risk of severe toxicity (Grade 3-4), thus maintaining a high Therapeutic Index:
- Validated Safety (Phase III clinical trials): Meta-analyses in Cervical Cancer demonstrate *no significant difference* in acute or late toxicity (RR Toxicity 1.01)[6]. The safety profile is maintained in Rectal Cancer[7] and Pancreatic Cancer trials.[8]
- Organ Preservation: In Rectal Cancer, the addition of HT to neoadjuvant chemoradiotherapy increases 5-year Colostomy-Free Survival (CFS) from 69.0% to *87.7%*, a major functional QoL benefit.[7]
- *Abscopal (Vaccin-Like) Effect:* HT triggers *immunogenic cell death, releasing *Heat Shock Proteins (HSPs)* that activate cytotoxic CD8+ T cells. This systemic immunologic first step contributes to the control of residual disease and is an essential adjuvant benefit.[9]
Conclusion: Patient-Centered Therapy
Integrating Hyperthermia into the oncology protocol represents an advanced, evidence-based strategy that not only improves Survival, but also provides robust symptom control and maintains Quality of Life. Pain relief, fatigue control and an excellent safety profile make HT an essential element of the holistic care of the oncology patient.
We invite you to consult our experts to integrate Hyperthermia into your protocol, with the aim of maximizing both effectiveness and Quality of Life.